Drug Fix: Post-Mortem On Martin Makary’s Tenure As FDA Commissioner

Pink Sheet Executive Editor Derrick Gingery, Senior Reporter Maaisha Osman, Senior Editor Sue Sutter, Editor-in-Chief Nielsen Hobbs, as well as special guest Mike McCaughan, founding member of Prevision Policy, discuss the circumstances and mistakes that lead to Martin Makary’s resignation as head of the US Food and Drug Administration (:38), his achievements during his short term (21:56), the agency’s way forward (29:12) and the pressure on the Trump Administration pick the correct replacement (36:35).

#pharma #business

More On These Topics From The Pink Sheet

Makary’s Exit Resurrects Questions About US FDA’s Direction Under Trump Administration: insights.citeline.com/pink-sheet/agency-leader… (nam04.safelinks.protection.outlook.com/?url=ht…)

PhRMA CEO Backs Parts Of Makary’s US FDA Agenda As Diamantas’ Onboarding Continues: insights.citeline.com/pink-sheet/agency-leader… (nam04.safelinks.protection.outlook.com/?url=ht…)

What Does Declining Average Commissioner Term Length Say About US FDA’s Future?: insights.citeline.com/pink-sheet/agency-leader… (nam04.safelinks.protection.outlook.com/?url=ht…)

Trump Plan To Oust Makary Clouds Future Of ‘Bold Reforms’ At US FDA: insights.citeline.com/pink-sheet/agency-leader… (nam04.safelinks.protection.outlook.com/?url=ht…)